{"links":{"feed":"https://www.erudio.com/reports/skb264-08-nct05631262/feed.json","html":"https://www.erudio.com/reports/skb264-08-nct05631262","json":"https://www.erudio.com/reports/skb264-08-nct05631262.json","markdown":"https://www.erudio.com/reports/skb264-08-nct05631262.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"skb264-08-nct05631262"}},"request":"https://www.erudio.com/contact?report=skb264-08-nct05631262"},"offer":{"cited_clinicians":7,"cited_commentary_sources":8,"verified_hcp_statements":62,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"verified_ids":{"included":"Every product, the free report included, comes with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself, inline on each person card under identifiers. Social accounts (X, Bluesky, LinkedIn) are not included. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Sample: https://www.erudio.com/report-sample.json","identity_verified_people":8},"for_sale":true,"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person; ask them for their work email and organization, both required. It returns the quote, a checkout_url for your person to pay by card and a pay_url your own payment client can pay over HTTP 402, with MPP (USDC on Tempo) or x402 (USDC on Base). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"required: the buyer's company or institution","product":["edition","updates-3","updates-6","updates-12"],"report":"skb264-08-nct05631262"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. Or pay it yourself: POST pay_url answers 402 Payment Required with both agent payment standards, MPP (USDC on Tempo) and x402 (USDC on Base); your payment client pays one. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=skb264-08-nct05631262","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/skb264-08-nct05631262","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_line":"Focused · 62 verified statements · 21 from 7 confirmed clinicians","size_rule":"Focused: 1–150 verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":{"applies_to":"Update plans (updates-3, updates-6, updates-12) only. Never a single edition (product edition), however many an account buys.","rule":"Volume discounts apply to update plans only: 15% off a plan when one account has update plans on 5 or more trials, 25% off from 10 or more. A single edition is never discounted, however many an account buys, and there are no other discounts.","tiers":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]}},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-19T09:42:43.702311Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":12,"no_commentary_found":0},"aspects":[{"claim_count":9,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":6,"title":"Primary endpoint: Objective Response Rate (ORR)"},{"claim_count":5,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":3,"title":"Primary endpoint: Incidence and severity of adverse events (AEs)"},{"claim_count":8,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":5,"title":"Secondary endpoints"},{"claim_count":8,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":6,"title":"Population and setting"},{"claim_count":9,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":5,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":3,"title":"Safety and tolerability"},{"claim_count":9,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":2,"coverage":"discussed","id":"A1","source_count":2,"title":"TROP2 IHC, selection and development-program expectations"},{"claim_count":1,"coverage":"discussed","id":"A2","source_count":1,"title":"Global applicability and reported Chinese licensing"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":1,"title":"Spanish access and possible research participation"},{"claim_count":1,"coverage":"discussed","id":"A4","source_count":1,"title":"Whether benefit will hold in light of experience with other TROP2 ADCs"},{"claim_count":5,"coverage":"discussed","id":"A5","source_count":2,"title":"Broader actionable-alteration cohorts, CNS evidence and next-study expectations"}],"counts":{"cited_clinicians":7,"cited_clinicians_by_role":{"physician":3,"physician, Medical oncology":4},"cited_physicians":7,"cited_sources":10,"claims_by_expression_type":{"comparison":5,"interpretation":26,"opinion":7,"primary_context":10,"question":5,"restatement":4,"uncertainty":3,"unspecified":2},"claims_by_kind":{"objective_result":7,"protocol_statement":1,"publication_statement":28,"source_observation":26},"clinician_statements":21,"evidence_units":34,"findings":8,"organisational_accounts":1,"people_cited":9,"people_identity_verified":8,"people_total":9,"screened_sources":19,"verified_claims":62},"findings_index":[{"cited_clinicians":4,"id":"F1","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":0,"questions":4,"restated":3,"views":8},"limitations":3,"links":{"context":0,"support":16},"ma_question":true,"named_voices":4,"passages":8,"sources":4,"sources_by_kind":{"commentary":3,"publication":1}},"title":"Primary ORR: some clinicians question it; some doubt registrational framing","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-e9d29cc60ebd5dc440de","claim-70e71b49c90be85f1cb6"],"clause":"some doubt registrational framing","holders":2},"cited_claim_ids":["claim-a042e21919f91dd32fde","claim-e9d29cc60ebd5dc440de"],"clinicians":true,"holders":2,"speakers":4,"view":"reading"},"evidence_line":"15 statements from 4 speakers in 4 sources","holder_line":"2 of the 4 named speakers in this finding hold this view, each a confirmed clinician; 2 of the 4 hold its caveat, “some doubt registrational framing”"},{"cited_clinicians":5,"id":"F2","structure":{"claims":11,"claims_by_group":{"comparisons":2,"experience":0,"questions":3,"restated":1,"views":5},"limitations":3,"links":{"context":2,"support":12},"ma_question":true,"named_voices":5,"passages":7,"sources":5,"sources_by_kind":{"commentary":4,"publication":1}},"title":"Sacituzumab tirumotecan: where clinicians split on confidence in its benefit","title_holders":{"cited_claim_ids":["claim-df6ff04fe126d758cef9","claim-955af4479e9b7c069e0a","claim-6406160e5b530e303292","claim-4ad7499cef374cf5cb3f","claim-616ddd4689a49cfadee2","claim-463834b6a19fea3046fb"],"clinicians":true,"holders":5,"sides":[{"cited_claim_ids":["claim-df6ff04fe126d758cef9","claim-955af4479e9b7c069e0a","claim-6406160e5b530e303292"],"holders":3},{"cited_claim_ids":["claim-4ad7499cef374cf5cb3f","claim-616ddd4689a49cfadee2","claim-463834b6a19fea3046fb"],"holders":2}],"speakers":5,"view":"split"},"evidence_line":"11 statements from 5 speakers in 5 sources","holder_line":"5 of the 5 named speakers in this finding take a side on this question: 3 on one side, 2 on the other; every named speaker in this finding is a confirmed clinician"},{"cited_clinicians":2,"id":"F3","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":5,"views":2},"limitations":3,"links":{"context":0,"support":9},"ma_question":true,"named_voices":2,"passages":8,"sources":4,"sources_by_kind":{"commentary":3,"publication":1}},"title":"OS interpretation: a clinician stresses immaturity and crossover despite ORR/PFS gains","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-0bf97cde6c533886f989","claim-955af4479e9b7c069e0a","claim-089a36f6fa530f7233c6","claim-8f472207a0964df8d0e5"],"clause":"despite ORR/PFS gains","holders":2},"cited_claim_ids":["claim-955af4479e9b7c069e0a"],"clinicians":true,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"8 statements from 2 speakers in 4 sources","holder_line":"1 of the 2 named speakers in this finding holds this view, a confirmed clinician; 2 of the 2 hold its caveat, “despite ORR/PFS gains”"},{"cited_clinicians":3,"id":"F4","structure":{"claims":13,"claims_by_group":{"comparisons":3,"experience":0,"questions":0,"restated":4,"views":6},"limitations":4,"links":{"context":0,"support":14},"ma_question":true,"named_voices":3,"passages":7,"sources":4,"sources_by_kind":{"commentary":3,"publication":1}},"title":"Safety: a clinician notes fewer grade ≥3 AEs; most flag specific toxicities","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-4b2195e59e7d86aeea6f","claim-336f2c1fa01d710748e6"],"clause":"most flag specific toxicities","holders":2},"cited_claim_ids":["claim-955af4479e9b7c069e0a","claim-089a36f6fa530f7233c6","claim-3d24bc3075eb2e80b748"],"clinicians":true,"holders":1,"speakers":3,"view":"reading"},"evidence_line":"13 statements from 3 speakers in 4 sources","holder_line":"1 of the 3 named speakers in this finding holds this view, a confirmed clinician; 2 of the 3 hold its caveat, “most flag specific toxicities”"},{"cited_clinicians":2,"id":"F5","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":1,"views":1},"limitations":2,"links":{"context":1,"support":3},"ma_question":true,"named_voices":2,"passages":3,"sources":3,"sources_by_kind":{"commentary":2,"publication":1}},"title":"TROP2 IHC: where clinicians split on its predictive role","title_holders":{"cited_claim_ids":["claim-78f2139fa2dae49fbdb4","claim-d40fd3e3c82a59d94154"],"clinicians":true,"holders":2,"sides":[{"cited_claim_ids":["claim-78f2139fa2dae49fbdb4"],"holders":1},{"cited_claim_ids":["claim-d40fd3e3c82a59d94154"],"holders":1}],"speakers":2,"view":"split"},"evidence_line":"3 statements from 2 speakers in 3 sources","holder_line":"2 of the 2 named speakers in this finding take a side on this question: 1 on one side, 1 on the other; every named speaker in this finding is a confirmed clinician"},{"cited_clinicians":1,"id":"F6","structure":{"claims":4,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":3},"limitations":2,"links":{"context":0,"support":4},"ma_question":true,"named_voices":1,"passages":2,"sources":2,"sources_by_kind":{"commentary":1,"publication":1}},"title":"Sacituzumab tirumotecan: a clinician calls for global data despite its China licence","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-53de8b4d535c0392c177"],"clause":"despite its China licence","holders":1},"cited_claim_ids":["claim-53de8b4d535c0392c177"],"clinicians":true,"holders":1,"speakers":1,"view":"reading"},"evidence_line":"4 statements from 1 speaker in 2 sources","holder_line":"The one named speaker in this finding holds this view, a confirmed clinician; 1 of them holds its caveat, “despite its China licence”"},{"cited_clinicians":1,"id":"F7","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":1},"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":2,"passages":2,"sources":1,"sources_by_kind":{"commentary":1}},"title":"Spain: a speaker notes delays; a clinician tentatively suggests trials","title_holders":{"caveat":{"among_lead":false,"cited_claim_ids":["claim-0c9b6fa639d9bb3cd5b7"],"clause":"a clinician tentatively suggests trials","holders":1},"cited_claim_ids":["claim-915478729e82f8ee1e60"],"clinicians":false,"holders":1,"speakers":2,"view":"reading"},"evidence_line":"2 statements from 2 speakers in 1 source","holder_line":"1 of the 2 named speakers in this finding holds this view; 1 of the 2 holds its caveat, “a clinician tentatively suggests trials”"},{"cited_clinicians":1,"id":"F8","structure":{"claims":6,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":2,"views":3},"limitations":4,"links":{"context":0,"support":7},"ma_question":true,"named_voices":2,"passages":4,"sources":3,"sources_by_kind":{"commentary":2,"publication":1}},"title":"Activity range: what speakers see; a clinician flags small N and scant CNS data","title_holders":{"caveat":{"among_lead":true,"cited_claim_ids":["claim-c0dadb131e6492abe190"],"clause":"a clinician flags small N and scant CNS data","holders":1},"cited_claim_ids":["claim-00dd1aff1fc5ddeb4abf","claim-3d0ed2ae9e512d0b0226"],"clinicians":false,"holders":2,"speakers":2,"view":"reading"},"evidence_line":"6 statements from 2 speakers in 3 sources","holder_line":"2 of the 2 named speakers in this finding hold this view; 1 of them holds its caveat, “a clinician flags small N and scant CNS data”"}],"open_question":{"basis":"From finding F1 (15 statements from 4 speakers in 4 sources)","cited_claim_ids":["claim-0bf97cde6c533886f989","claim-a042e21919f91dd32fde","claim-e9d29cc60ebd5dc440de","claim-4ad7499cef374cf5cb3f","claim-616ddd4689a49cfadee2","claim-70e71b49c90be85f1cb6","claim-089a36f6fa530f7233c6","claim-57ee5176f641d0aeae08","claim-69ced28ccbdb85038511","claim-513efbba4e90bf2d8301","claim-30e70df6d1096e3dc02f","claim-84987433ece03f2e4cfc","claim-fc0e130a79c80a7e3024"],"finding_ids":["F1"],"question":"What do clinicians say would resolve concerns about OptiTROP-Lung03’s ORR primary endpoint and PFS reliability for sac-TMT versus docetaxel in advanced EGFR-mutated NSCLC after EGFR-TKI and platinum chemotherapy?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Clinicians question endpoint choices and registrational framing"},{"id":"section-2","level":2,"title":"Clinicians welcome the promise; one presentation relay questions whether benefit will hold"},{"id":"section-3","level":2,"title":"One clinician stresses immature OS and crossover despite welcoming ORR and PFS"},{"id":"section-4","level":2,"title":"One clinician highlights fewer severe adverse events; presentation coverage flags specific toxicities"},{"id":"section-5","level":2,"title":"Presentation coverage asserts TROP2-IHC prediction; one clinician leaves it as a question"},{"id":"section-6","level":2,"title":"One clinician calls for global data despite reported licensing in China"},{"id":"section-7","level":2,"title":"One X account reports Spanish access barriers; a clinician suggests trial access only tentatively"},{"id":"section-8","level":2,"title":"Two X accounts highlight broader molecular activity; one clinician warns about small numbers and sparse CNS data"},{"id":"section-9","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":5},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":3},{"id":"F6","shared_claims":1}],"id":"T1","label":"Primary endpoint: Objective Response Rate (ORR)"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":5},{"id":"F6","shared_claims":1}],"id":"T2","label":"Primary endpoint: Incidence and severity of adverse events (AEs)"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":5},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":3},{"id":"F6","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F2","shared_claims":5},{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":3},{"id":"F6","shared_claims":2}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":5},{"id":"F6","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":5},{"id":"F6","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":9},{"id":"F2","shared_claims":3},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":2}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-19T09:42:43.702311Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-19T11:23:26Z","record_hash":"c1f1d68ed27d0e3bbdfe480c54303a51a14a115bb00fb0b3f12a0e6d897c533d","release_hash":"ec8465801654378542bd8a6e6a7938f24359b2536ff4ee8000c655e82e0557ef","report_id":"erudio-nct05631262","run_id":"fbca6ba2-3225-41c4-951c-2ba7ce05d811","schema_version":"5.0","slug":"skb264-08-nct05631262","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"Some cited clinicians read SKB264-Ⅱ-08 favorably for tumour-response gains, while a medical oncologist rejects its characterization as registrational, citing docetaxel’s performance. A different medical oncologist combines a favorable benefit–risk reading with questions about prioritizing tumour response. Their interpretation remains qualified by immature survival data and a call for evidence beyond China.","examples":[],"meta_description":"19 sources screened · 62 verified statements (21 from clinicians verified by NPI or staff page) from 10 sources · 8 findings. Updated Nov 19, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-19T11:23:26Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":19},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","10 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 52 sources about other trials or topics are not included.","Discussion may be missing when a source used an unnamed reference, a different spelling or another way of describing the study. The report should not be read as exhaustive public sentiment.","Public X reactions, presenter relays and publication summaries do not establish independent clinician counts, consensus, prescribing behavior or patient outcomes in routine care.","A separate protocol and an exact SKB264 regulatory label were not available among the documents reviewed. Regulatory-endpoint and licensing statements therefore remain attributed accounts rather than independently confirmed requirements or indications.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The June 2025 randomized-comparison discussion and the September 2026 molecularly broader posts address different settings. Post dates and meeting hashtags do not establish session dates or changes in opinion.","Some reported descriptions differ, including phase 2 versus phase 3 labeling and OS hazard ratios. The report preserves those differences rather than creating a reconciled estimate."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":2,"registry":0,"regulatory":0,"x_thread":8,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":8,"results":2},"count":10,"evidence_window":{"end":"2026-09-14","start":"2025-06-01"},"retrieval_snapshot":"2026-11-19T09:13:07.841188Z","timeline":[{"count":5,"week":"2025-W22"},{"count":2,"week":"2025-W23"},{"count":2,"week":"2026-W38"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT05631262:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT05631262:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:40210967","quote_policy":"short_quote_link_out"},{"id":"pubmed:40473437","quote_policy":"short_quote_link_out"},{"id":"openfda:3538b979-8cac-49ed-b8dc-50f73ce38c72:20261019","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-bvs6b4f4fz2jj73wtrtjiy4j-3lqs4tjmquy2u","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3mhutgfzrkn2c","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-zwaxkm7x44me7z7nwpagim42-3midxtwkyst27","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1911404002488861057:5c0b198b-33b5-4305-bb1f-f6286cd089b7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929195406472184038:ccbde8a8-af10-4e02-b695-b07f60daa1ed","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929195654066192796:2b444357-923f-4bee-a41d-fee50aa6f34f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929196514234048924:cba904de-0d96-4b09-8c80-6db413b4ecdc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929198736313364904:34238442-9493-4424-aa3b-13adadab88eb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929201101024137513:c9d929ea-ad05-4ecb-bdd2-1422133c1012","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1929212056357507075:0af8bd21-1f3b-48b8-88e8-4584c3b148e8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1930639313160859970:6077c136-3026-420d-b206-69f84bd19467","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1931378885679026273:d6ad9be2-9861-4129-9170-3e12626a4c6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1974104651210580245:cfee4c5c-dcae-48d0-96b5-5e5a3211ff8b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2037063573457764729:521d0a7f-f1cb-4e21-b265-2ec5eb7c580e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090386863064502272:a03ae630-b696-4217-a1d1-ad2c45754195","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2091145462023967222:7c244b39-d780-456f-9488-990922ae8163","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099339451000557638:74b8012e-ae48-479a-a1e9-fde88e332627","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099342659739623688:8a724ef2-b42c-483a-905d-1efbef8f4c6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099390637577588952:42342d63-41e3-4b12-9fe6-e836b4df9811","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":16,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":19},"count":19,"evidence_window":{"end":"2026-09-14","start":"2025-04-13"},"retrieval_snapshot":"2026-11-19T09:13:07.874160Z","timeline":[{"count":1,"week":"2025-W15"},{"count":6,"week":"2025-W22"},{"count":4,"week":"2025-W23"},{"count":1,"week":"2025-W40"},{"count":2,"week":"2026-W13"},{"count":1,"week":"2026-W14"},{"count":2,"week":"2026-W34"},{"count":3,"week":"2026-W38"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":36,"registry":0,"regulatory":0,"x_thread":26,"x_video":0,"youtube":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"brand_names":{"reason":"No checked-in brand mapping.","status":"unmapped"},"label":"sacituzumab tirumotecan","slug":"sacituzumab-tirumotecan"},{"brand_names":["Taxotere"],"label":"docetaxel","slug":"docetaxel"}],"indications":[{"reason":"Unmapped registry condition: Selected Subjects With Advanced Solid Tumors","status":"unmapped"},{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Advanced solid tumors","slug":"advanced-solid-tumors"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"aliases":["SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors"],"brief_title":"SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Selected Subjects With Advanced Solid Tumors"],"display_condition":"advanced solid tumors","display_interventions":[["sacituzumab tirumotecan"]],"enrollment":{"count":321,"type":"ACTUAL"},"interventions":[{"name":"SKB264","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Docetaxel","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT05631262","official_title":"A Multicenter, Open-label, Phase 2 Study to Evaluate the Efficacy and Safety of SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE2"],"primary_completion_date":{"date":"2026-12-30","type":"ESTIMATED"},"primary_endpoints":[{"description":"ORR is defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR) as the best overall response assessed per RECIST 1.1.","measure":"Objective Response Rate (ORR)","timeFrame":"From baseline until disease progression, death, or other protocol defined reason, up to approximately 21 months."},{"description":"Incidence and severity of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE) v5.0.","measure":"Incidence and severity of adverse events (AEs)","timeFrame":"From subject sign the informed consent form (ICF) to 30 days after the last dose of study treatment."}],"registered_date":{"date":"2022-11-30","type":"ACTUAL"},"registry_last_updated":"2026-05-08","registry_url":"https://clinicaltrials.gov/study/NCT05631262","short_name":"SKB264-Ⅱ-08","short_name_basis":"sponsor_study_id","sponsor":"Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.","start_date":{"date":"2022-11-30","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2","study_ids":[{"id":"SKB264-Ⅱ-08","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}